- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05400512
Miglioramento cognitivo nella depressione (lo studio COG-D)
Neuromodulazione non invasiva per migliorare la correzione cognitiva mirata negli anziani con depressione
This study will investigate whether transcranial direct current stimulation (tDCS) enhances the effects of computerized cognitive training in older adults with recurrent depression (2 or more lifetime episodes; either current or within past 3 years).
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The purpose of this study is to determine whether the addition of active tDCS to computerized cognitive remediation (nCCR) enhances brain activity and cognitive functions in older adults with recurrent depression to a greater degree than nCCR with sham stimulation. The investigators will randomize 20 elderly depressed outpatients to either double-blinded active or sham bifrontal tDCS plus daily nCCR over 4-weeks. Multimodal MRI (focused on the cognitive control network; CCN) and psychiatric and neuropsychological evaluations will be obtained at baseline and following intervention completion. Long-term CCN cognitive effects will be explored 3-months post-intervention via cognitive assessments.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37212
- Vanderbilt University Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 60+ years
- Diagnosis of a current or past (within last 3 years) depressive episode (e.g., Major Depressive Disorder (MDD), Persistent Depressive Disorder (PDD)) using Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria
- In total, participants must have 2 or more lifetime depressive episodes to be considered "recurrent"
- Either stable antidepressant regimen for at least 6 weeks or no current antidepressant treatment
- Evidence of subjective cognitive complaints on the Everyday Cognition Scale (ECog)
- English fluency
Exclusion criteria:
- Other Axis I psychiatric conditions via the DSM-5, except for anxiety symptoms occurring in a depressive episode
- Acute suicidality on clinical evaluation
- Acute grief
- History of alcohol use disorder or substance use disorder in last 12 months
- Currently taking medications that would significantly interact with tDCS effects (such as sodium channel blockers or anticonvulsants)
- Neurological disorders (e.g., dementia, stroke, seizures, traumatic brain injury, Parkinson's disease)
- Montreal Cognitive Assessment (MoCA) score < 23
- Primary amnestic cognitive profile (>1.5 standard deviations (SDs) below demographically-adjusted mean on National Alzheimer's Coordinating Center (NACC) memory measures in context of otherwise normal cognitive profile)
- Any physical or intellectual disability affecting ability to complete assessments
- Unstable medical illness needing urgent treatment
- MRI contraindications
- Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) in last 2 months
- Current involvement in psychotherapy
- Current involvement in other research studies (including but not limited to: neuromodulation [TMS or tDCS] or investigational drug studies)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Cognitive Training + Active Stimulation
This arm receives cognitive training combined with active tDCS. |
Computerized cognitive training targeting the underlying cerebral networks associated with depression. A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0 milliamps (mA) direct current through two bicarbon rubber electrodes encased in saline soaked 5 cm x 7 cm sponges (8 cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (via 10-20 system). |
|
Sperimentale: Cognitive Training + Sham Stimulation
This arm receives cognitive training combined with sham tDCS. |
Computerized cognitive training targeting the underlying cerebral networks associated with depression. Sham stimulation will be performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Task-based fMRI Activation Within the Cognitive Control Network During the N-back Task
Lasso di tempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
MRI scans were performed at baseline (T1) and after completion of the intervention (4 to 6 weeks later; T2). MRI measured Cognitive Control Network function, operationalized as change in n-back functional MRI response in the anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (DLPFC), and the posterior parietal cortex (PPC) regions of interest. The n-back functional MRI response was calculated as the activation difference (beta values) between 2-back and 0-back conditions of the n-back. Higher scores indicate more activation during the 2-back condition compared to the 0-back condition. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
|
N-back Behavioral Performance (Accuracy)
Lasso di tempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Target accuracy data on the n-back were extracted for each n-back condition (2-back and 0-back). Higher scores for the metrics indicated better accuracy. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
|
N-back Behavioral Performance (Response Time)
Lasso di tempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Target response time data on the n-back were extracted for each n-back condition (2-back and 0-back). Lower scores indicate faster response times. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
|
NIH Examiner Scores
Lasso di tempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Computerized neuropsychological battery to assess range of executive functions. The Executive Composite represents overall executive function performance across multiple neuropsychological measures. Item Response Theory (IRT) Empirical Bayes scoring based on the saved parameters from the 3 factors (Working Memory, Cognitive Control, Fluency) are used to generate scores, which are not a norm-referenced measure and are not adjusted for age. The composite is presented in the original metric used in the IRT algorithm. Scores range from -1.50 to 1.52. Higher scores mean better executive function. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
California Verbal Learning Test, 2nd Edition (CVLT-2) Scores
Lasso di tempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
The California Verbal Learning Test, 2nd edition (CVLT-2) is a standardized measure of verbal learning and memory. Raw scores are obtained and converted to age and sex-adjusted z-scores, with 0 indicating population average. Positive values indicate of better than average learning and memory performances. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Montgomery Asberg Depression Rating Scale (MADRS) Scores)
Lasso di tempo: From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Depression rating scale that ranges from 0-60, with higher scores indicating greater depressive symptom severity. For percent change, post-intervention (T2) was compared to baseline (T1), with higher negative values indicating greater decrease in depressive symptoms at T2 compared to baseline. |
From baseline (T1) to post-intervention (4-6 weeks; T2)
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Sarah M. Szymkowicz, PhD, Vanderbilt University Medical Center
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Manifestazioni neurologiche
- Malattie del sistema nervoso
- Sintomi comportamentali
- Condizioni patologiche, segni e sintomi
- Comportamento
- Segni e sintomi
- Depressione
- Manifestazioni neurocomportamentali
- Terapie
- Cura del paziente
- Servizi sanitari
- Force di lavoro e servizi per le strutture sanitarie
- Discipline e attività comportamentali
- Riabilitazione
- Assistenza post -terapia
- Continuità della cura del paziente
- Terapia di stimolazione elettrica
- Terapia convulsiva
- Terapie somatiche psichiatriche
- Elettroshock
- Tecniche psicologiche
- Riabilitazione neurologica
- Stimolazione transcranica di corrente continua
- Allenamento cognitivo
Altri numeri di identificazione dello studio
- 220283
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .